Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 424
- Registration Number
- NCT02303587
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02294357
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Blood & Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Mehrdad Abedi, MD
- Target Recruit Count
- 10
- Registration Number
- NCT02293109
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 111
- Registration Number
- NCT02292082
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT02282514
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Rituximab and Belimumab for Lupus Nephritis
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2020-12-01
- Target Recruit Count
- 43
- Registration Number
- NCT02260934
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸Colorado Kidney Care, Denver, Colorado, United States
Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Brugmann University Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT02252809
Maternal Epidural Steroids and Hyperthemia
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 135
- Registration Number
- NCT02212210
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 58
- Registration Number
- NCT02205489
- Locations
- 🇧🇪
Investigational Site Number 056001, Brussels, Belgium
🇳🇱Investigational Site Number 528001, Breda, Netherlands
🇳🇱Investigational Site Number 528002, Rotterdam, Netherlands
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.